Skip to content
Elizabeth Holmes- Case Archive
personpersonTyler ShultzTyler ShultzFormer Theranos employee and whistleblower who raised concerns about the company's laboratory practices.← All People
MentionedTheranos

Tyler Shultz

Former Theranos employee and whistleblower who raised concerns about the company's laboratory practices.

MentionedFederal Criminal Trial
15 proceedings·15 mentions

About

Tyler Shultz worked with Erika Cheung at Theranos in research and development and on validation work. Cheung testified that she sent him comparative proficiency-testing data, knew he had communicated concerns about proficiency testing, assay validation, and quality control to Elizabeth Holmes, and joined him in discussing laboratory conditions with a board member.

The court admitted Shultz's email to Holmes only to show notice, not to establish the truth of its assertions, and later reiterated that limitation. Holmes testified that she directed Daniel Young to investigate his concerns. Her later examination addressed Shultz's departure, Theranos's legal response to suspected sources for Wall Street Journal reporting, and company correspondence involving him. Kingshuk Das also testified that he was not initially told about Shultz or the earlier internal quality-control concerns when he joined the laboratory.

Trial Record (15)

FederalFederal Criminal TrialAug 31, 2021 – Jan 3, 2022

Tyler Shultz worked with Erika Cheung at Theranos, received proficiency-testing data from her, and raised laboratory concerns with Elizabeth Holmes. The court admitted his email to Holmes only to show notice, not to establish the truth of its assertions.

Jury Selection Day 2

Day 7

DirectErika Cheung — DirectErika CheungJohn C. Bostic1highlightMentioned

Summary

Cheung described recurring Edison QC failures, manual outlier removal, disparities in proficiency testing, internal warnings, and her eventual decision to leave Theranos and report concerns externally.

Mentioned in this proceeding.

Highlights (1)

evidence eventThe court admitted Tyler Shultz's email to Elizabeth Holmes solely to show notice, and later admitted the law-firm letter delivered to Cheung; Cheung said she subsequently contacted CMS about the laboratory concerns.Open in transcript →
CrossErika Cheung — CrossErika CheungLance A. WadeMentioned

Summary

Defense counsel emphasized Theranos's trained laboratory teams, formal validation reports, multiple approvals, and written operating procedures while narrowing Cheung's personal expertise. Cheung agreed that QC preceded patient testing but maintained that validation was sometimes compressed, written procedures differed from practice, and frequent reader failures required extensive recalibration.

Mentioned in this proceeding.

Day 8

CrossErika Cheung — CrossErika CheungLance A. WadeMentioned

Summary

Defense counsel used laboratory procedures, email chains, workflow improvements, and a sample-volume patent to emphasize Theranos's monitoring and remediation systems and to narrow Cheung's expertise. Cheung nevertheless maintained that the vitamin D SOP was not followed, confirmed that hepatitis C was not run on Edison after her concerns, and described Edison as a one-patient, one-test device.

Mentioned in this proceeding.

Day 10

ProceduralText Message Admissibility Hearing and RulingsMentioned

Summary

The court resolved disputed Rule 106 text-message designations, allowed journalist-related messages for notice and knowledge with a limiting instruction, ordered one name redacted, and left other evidentiary objections open.

Mentioned in this proceeding.

Day 31

RedirectKingshuk Das — RedirectKingshuk DasRobert S. Leach1highlightMentioned

Summary

Das clarified that the next-generation device was not used clinically, described Holmes's control over laboratory resources, and said broader quality-control data supported voiding tests despite disagreement over how to characterize the problems.

Mentioned in this proceeding.

Highlights (1)

testimony highlightDas testified that no one initially told him about earlier internal quality-control concerns, Erika Cheung, Tyler Shultz, or the circumstances of Adam Rosendorff's departure.Open in transcript →

Day 39

DirectElizabeth A. Holmes — DirectElizabeth A. HolmesKevin M. Downey1highlightMentioned

Summary

Holmes described Theranos's military projects, demonstrations, laboratory oversight, and regulatory history before giving emotional testimony alleging coercion and sexual abuse by Ramesh Balwani. She denied that Balwani forced her investor or press statements, addressed the 2015 CMS failures and later remediation, and said she never sold her Theranos shares.

Mentioned in this proceeding.

Highlights (1)

testimony highlightHolmes testified that she directed Daniel Young to investigate Tyler Shultz's concerns and accepted Young's explanation after he reported consultation with regulatory personnel and laboratory leadership.Open in transcript →

Day 40

CrossElizabeth A. Holmes — CrossElizabeth A. HolmesRobert S. Leach1highlightMentioned

Summary

Holmes's cross-examination covered Theranos's response to critical reporting and whistleblowers, her control of the company, limits on Theranos devices, and Balwani's influence. She acknowledged major mistakes in the Wall Street Journal response, extensive reliance on commercial equipment, and problems with pharmaceutical-branded reports while disputing retaliation and several prosecutorial characterizations.

Mentioned in this proceeding.

Highlights (1)

confrontationThe prosecution traced Tyler Shultz's technical and public-claims concerns through admitted emails, Holmes's comments on a forceful response, his departure, and later efforts to have him sign documents. Holmes acknowledged that Theranos ultimately voided the vitamin D results and that the handling of the Wall Street Journal process was a disaster, while denying retaliation.Open in transcript →

Day 42

RedirectElizabeth A. Holmes — RedirectElizabeth A. HolmesKevin M. Downey1highlightMentioned

Summary

Holmes used redirect to explain Theranos's laboratory oversight, modified analyzers, financial projections, partner reports, trade-secret restrictions, and responses to Tyler Shultz. She attributed operational and technical work to others while acknowledging authority over investor presentations and explaining nondisclosure of modified systems as trade-secret protection.

Mentioned in this proceeding.

Highlights (1)

testimony highlightThe defense revisited Tyler Shultz's assay and marketing concerns through email chains and draft responses. Holmes testified that she understood Daniel Young to view Shultz's coefficient-of-variation calculations as mistaken and explained Theranos's accuracy claims in terms of standardized testing and longitudinal trends.Open in transcript →

Day 45

Day 46

ClosingClosing Argument by the ProsecutionJeff SchenkMentioned

Summary

The prosecution argued that Holmes knowingly deceived investors and patients, linked the documentary and testimonial record to the conspiracy and wire-fraud elements, rebutted the principal defense themes, and requested guilty verdicts on all remaining counts.

Mentioned in this proceeding.

Day 47